MX2022011562A - Métodos y composiciones para edición dirigida de genoma. - Google Patents
Métodos y composiciones para edición dirigida de genoma.Info
- Publication number
- MX2022011562A MX2022011562A MX2022011562A MX2022011562A MX2022011562A MX 2022011562 A MX2022011562 A MX 2022011562A MX 2022011562 A MX2022011562 A MX 2022011562A MX 2022011562 A MX2022011562 A MX 2022011562A MX 2022011562 A MX2022011562 A MX 2022011562A
- Authority
- MX
- Mexico
- Prior art keywords
- nucleic acid
- reverse transcriptase
- guide nucleic
- compositions
- cas9 nickase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/122—Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/123—Hepatitis delta
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/128—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes processing or releasing ribozyme
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062992032P | 2020-03-19 | 2020-03-19 | |
| US202063055829P | 2020-07-23 | 2020-07-23 | |
| US202163153161P | 2021-02-24 | 2021-02-24 | |
| PCT/US2021/023041 WO2021188840A1 (en) | 2020-03-19 | 2021-03-18 | Methods and compositions for directed genome editing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022011562A true MX2022011562A (es) | 2022-12-13 |
Family
ID=77747638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022011562A MX2022011562A (es) | 2020-03-19 | 2021-03-18 | Métodos y composiciones para edición dirigida de genoma. |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US11352623B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4121522A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023518395A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230003467A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115667505A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021236683A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022011562A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021188840A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019051097A1 (en) | 2017-09-08 | 2019-03-14 | The Regents Of The University Of California | RNA-GUIDED ENDONUCLEASE FUSION POLYPEPTIDES AND METHODS OF USING SAME |
| WO2019217942A1 (en) | 2018-05-11 | 2019-11-14 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| EP3820495A4 (en) | 2018-07-09 | 2022-07-20 | The Broad Institute Inc. | RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES |
| EP3850088A4 (en) | 2018-09-07 | 2023-07-19 | Beam Therapeutics, Inc. | Compositions and methods for improving base editing |
| KR20210055733A (ko) | 2018-09-07 | 2021-05-17 | 빔 테라퓨틱스, 인크. | 핵염기 편집 시스템을 전달하기 위한 조성물 및 방법 |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| JP7646552B2 (ja) | 2019-01-31 | 2025-03-17 | ビーム セラピューティクス インク. | 低減された非標的脱アミノ化を有する核酸塩基エディターおよび核酸塩基エディターの特徴づけのためのアッセイ |
| WO2020168135A1 (en) | 2019-02-13 | 2020-08-20 | Beam Therapeutics Inc. | Compositions and methods for treating alpha-1 antitrypsin deficiency |
| US12600971B2 (en) | 2019-02-13 | 2026-04-14 | Beam Therapeutics Inc. | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence |
| WO2020191241A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| WO2020214842A1 (en) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| US20220259617A1 (en) | 2019-06-13 | 2022-08-18 | The General Hospital Corporation | Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells |
| US12594301B2 (en) | 2019-09-27 | 2026-04-07 | Beam Therapeutics Inc. | Compositions and methods for treatment of liquid cancers |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| BR112022017715A2 (pt) | 2020-03-04 | 2022-11-16 | Flagship Pioneering Innovations Vi Llc | Métodos e composições para modular um genoma |
| WO2021188840A1 (en) | 2020-03-19 | 2021-09-23 | Rewrite Therapeutics, Inc. | Methods and compositions for directed genome editing |
| CA3177481A1 (en) * | 2020-05-08 | 2021-11-11 | David R. Liu | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| BR112023001272A2 (pt) | 2020-07-24 | 2023-04-04 | Massachusetts Gen Hospital | Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células |
| AU2021347359A1 (en) | 2020-09-25 | 2023-05-18 | Beam Therapeutics Inc. | Fratricide resistant modified immune cells and methods of using the same |
| KR20230091894A (ko) | 2020-10-21 | 2023-06-23 | 메사추세츠 인스티튜트 오브 테크놀로지 | 부위 특이적 표적화 요소를 통한 프로그램 가능한 첨가(paste)를 사용하는 부위 특이적 유전 공학을 위한 시스템, 방법, 및 조성물 |
| WO2022098765A1 (en) * | 2020-11-03 | 2022-05-12 | The Board Of Trustees Of The University Of Illinois | Split prime editing platforms |
| EP4370672A4 (en) * | 2021-07-16 | 2025-07-09 | Prime Medicine Inc | GENOME EDITING COMPOSITIONS AND METHODS FOR TREATING WILSON'S DISEASE |
| EP4392039A4 (en) * | 2021-08-24 | 2025-10-15 | Prime Medicine Inc | GENOME EDITING COMPOSITIONS AND METHODS FOR TREATING RETINOPATHY |
| KR20260037664A (ko) | 2021-09-08 | 2026-03-18 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 게놈을 조절하기 위한 방법 및 조성물 |
| US20240425831A1 (en) * | 2021-10-08 | 2024-12-26 | The General Hospital Corporation | Improved crispr prime editors |
| CA3235826A1 (en) * | 2021-10-21 | 2023-04-27 | Wei Hsi Yeh | Genome editing compositions and methods for treatment of usher syndrome type 3 |
| US20230151353A1 (en) * | 2021-11-12 | 2023-05-18 | Replace Therapeutics, Inc. | Direct replacement genome editing |
| US11866728B2 (en) | 2022-01-21 | 2024-01-09 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
| CN116555335A (zh) * | 2022-01-30 | 2023-08-08 | 上海科技大学 | 一种可调节的先导编辑器及其应用 |
| EP4540389A2 (en) | 2022-06-16 | 2025-04-23 | Intellia Therapeutics, Inc. | Compositions and methods for reducing mhc class i in a cell |
| CN115029374B (zh) * | 2022-06-24 | 2023-12-26 | 安徽省农业科学院水稻研究所 | 一种用于骨干载体的pegRNA表达框及相应骨干载体和应用 |
| JP2025525569A (ja) | 2022-07-18 | 2025-08-05 | レナゲード セラピューティクス マネージメント インコーポレイテッド | 遺伝子編集成分、システム、及び使用方法 |
| WO2024042489A1 (en) | 2022-08-25 | 2024-02-29 | LifeEDIT Therapeutics, Inc. | Chemical modification of guide rnas with locked nucleic acid for rna guided nuclease-mediated gene editing |
| IL320573A (en) | 2022-11-04 | 2025-07-01 | Life Edit Therapeutics Inc | Developed adenine deaminases and RNA-guided nuclease fusion proteins with internal insertion sites and methods of use |
| WO2024127370A1 (en) | 2022-12-16 | 2024-06-20 | LifeEDIT Therapeutics, Inc. | Guide rnas that target trac gene and methods of use |
| WO2024127369A1 (en) | 2022-12-16 | 2024-06-20 | LifeEDIT Therapeutics, Inc. | Guide rnas that target foxp3 gene and methods of use |
| WO2024178397A2 (en) | 2023-02-24 | 2024-08-29 | Elevatebio Technologies, Inc. | Modified immune effector cells and methods of use |
| CN117511906A (zh) * | 2023-03-14 | 2024-02-06 | 中国农业大学 | 一种高效的Csy4核酸酶切割介导的多基因引导编辑系统CMPE及相关蛋白 |
| EP4750890A2 (en) | 2023-07-27 | 2026-06-03 | Life Edit Therapeutics, Inc. | Rna-guided nucleases and active fragments and variants thereof and methods of use |
| WO2025038646A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Cd70 car-t compositions and methods for cell-based therapy |
| WO2025038637A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2) |
| WO2025038648A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2) |
| TW202515994A (zh) | 2023-08-14 | 2025-04-16 | 美商英特利亞醫療公司 | 用於對cd70進行基因修飾之組合物及方法 |
| EP4771154A2 (en) | 2023-09-01 | 2026-07-08 | Renagade Therapeutics Management Inc. | Gene editing systems, compositions, and methods for treatment of vexas syndrome |
| WO2025076306A1 (en) * | 2023-10-06 | 2025-04-10 | University Of Massachusetts | Prime editors having improved prime editing efficiency |
| EP4791895A1 (en) * | 2023-10-12 | 2026-08-19 | The University of Chicago | Methods and compositions for characterizing rna-binding protein binding sites by in-situ reverse transcription-based sequencing |
| CN122422501A (zh) | 2023-10-18 | 2026-07-17 | 生命编辑治疗股份有限公司 | Rna引导的核酸酶及其活性片段和变体以及使用方法 |
| WO2025106766A1 (en) * | 2023-11-15 | 2025-05-22 | Yale University | Fusion-modified enzyme constructs |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025155753A2 (en) | 2024-01-17 | 2025-07-24 | Renagade Therapeutics Management Inc. | Improved gene editing system, guides, and methods |
| WO2025174765A1 (en) | 2024-02-12 | 2025-08-21 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025174908A1 (en) | 2024-02-12 | 2025-08-21 | Life Edit Therapeutics, Inc. | Novel rna-guided nucleases and proteins for polymerase editing |
| WO2025226730A1 (en) * | 2024-04-22 | 2025-10-30 | Transit Therapeutics, Inc. | Revision of genetic material using direct replacement editing |
| WO2025235506A2 (en) * | 2024-05-06 | 2025-11-13 | Flagship Pioneering Innovations Vi, Llc | Atp7b-modulating compositions and methods |
| WO2025255308A1 (en) | 2024-06-07 | 2025-12-11 | Intellia Therapeutics, Inc. | Cd8 co-receptor chimeric polypeptides in tcr cell therapy |
| WO2025264736A1 (en) * | 2024-06-18 | 2025-12-26 | Blake Richards | Logic capable protease probes and uses thereof |
| TW202617985A (zh) | 2024-06-25 | 2026-05-01 | 美商生命編輯治療學公司 | 新穎反轉錄酶及其用途 |
| WO2026064481A1 (en) * | 2024-09-20 | 2026-03-26 | Harpe Bioherbicide Solutions, Inc. | Glucosyltransferase genes conferring herbicide tolerance |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0999275B1 (en) * | 1998-10-12 | 2005-01-19 | Roche Diagnostics GmbH | Deoxynucleoside kinase from insect cells for the synthesis of nucleoside monophosphates |
| GB0806562D0 (en) * | 2008-04-10 | 2008-05-14 | Fermentas Uab | Production of nucleic acid |
| WO2011116184A2 (en) | 2010-03-17 | 2011-09-22 | Cornell University | Methods and compositions for targeted mutagenesis in bacteria |
| FR2973040B1 (fr) * | 2011-03-23 | 2016-04-15 | Centre Nat De La Rech Scient (C N R S) | Methode de criblage de composes antiretroviraux et vaccin |
| CA2841541C (en) * | 2011-07-25 | 2019-11-12 | Sangamo Biosciences, Inc. | Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (cftr) gene |
| ES2728782T3 (es) | 2012-05-25 | 2019-10-28 | Univ California | Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN |
| ES2749624T3 (es) * | 2013-03-14 | 2020-03-23 | Caribou Biosciences Inc | Composiciones y métodos de ácidos nucleicos dirigidos a ácido nucleico |
| WO2014186686A2 (en) | 2013-05-17 | 2014-11-20 | Two Blades Foundation | Targeted mutagenesis and genome engineering in plants using rna-guided cas nucleases |
| US20150044772A1 (en) | 2013-08-09 | 2015-02-12 | Sage Labs, Inc. | Crispr/cas system-based novel fusion protein and its applications in genome editing |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| US20150166984A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting alpha-antitrypsin point mutations |
| US9963687B2 (en) | 2014-08-27 | 2018-05-08 | New England Biolabs, Inc. | Fusion polymerase and method for using the same |
| WO2016036754A1 (en) | 2014-09-02 | 2016-03-10 | The Regents Of The University Of California | Methods and compositions for rna-directed target dna modification |
| EP3845655B1 (en) * | 2014-10-01 | 2025-01-01 | The General Hospital Corporation | Methods for increasing efficiency of nuclease-induced homology-directed repair |
| CN107614680A (zh) | 2015-05-14 | 2018-01-19 | 南加利福尼亚大学 | 利用重组核酸内切酶系统的最佳化基因编辑 |
| CA3001683C (en) | 2015-06-05 | 2024-06-04 | The Regents Of The University Of California | Methods and compositions for generating crispr/cas guide rnas |
| WO2016205671A1 (en) * | 2015-06-17 | 2016-12-22 | The Trustees Of Columbia University In The City Of New York | Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial dna depletion syndromes |
| US9926546B2 (en) | 2015-08-28 | 2018-03-27 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases |
| WO2017070632A2 (en) | 2015-10-23 | 2017-04-27 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
| EP3163302A1 (en) * | 2015-11-02 | 2017-05-03 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Samhd1 modulation for treating resistance to cancer therapy |
| WO2017106616A1 (en) | 2015-12-17 | 2017-06-22 | The Regents Of The University Of Colorado, A Body Corporate | Varicella zoster virus encoding regulatable cas9 nuclease |
| US11447768B2 (en) | 2016-03-01 | 2022-09-20 | University Of Florida Research Foundation, Incorporated | Molecular cell diary system |
| EP3426353A4 (en) * | 2016-03-09 | 2020-05-06 | The University of Massachusetts | USE OF MODIFIED HIV-1 TO GENERATE FULLY HUMAN ANTIBODIES |
| CA3026110A1 (en) | 2016-04-19 | 2017-11-02 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
| WO2018027078A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Adenosine nucleobase editors and uses thereof |
| EP4431607A3 (en) * | 2016-09-09 | 2024-12-11 | The Board of Trustees of the Leland Stanford Junior University | High-throughput precision genome editing |
| WO2018106732A1 (en) * | 2016-12-05 | 2018-06-14 | Juno Therapeutics, Inc. | Production of engineered cells for adoptive cell therapy |
| CN110914310A (zh) | 2017-03-10 | 2020-03-24 | 哈佛大学的校长及成员们 | 胞嘧啶至鸟嘌呤碱基编辑器 |
| IL306092A (en) | 2017-03-23 | 2023-11-01 | Harvard College | Nucleic base editors that include nucleic acid programmable DNA binding proteins |
| WO2019051097A1 (en) | 2017-09-08 | 2019-03-14 | The Regents Of The University Of California | RNA-GUIDED ENDONUCLEASE FUSION POLYPEPTIDES AND METHODS OF USING SAME |
| WO2019070843A1 (en) * | 2017-10-03 | 2019-04-11 | Board Of Regents, The University Of Texas System | INVERSE TRANSCRIPTASE WITH LTR-FREE BACKLIGHTS AND USES THEREOF |
| US20210261957A1 (en) * | 2018-07-10 | 2021-08-26 | Alia Therapeutics S.R.L. | Vesicles for traceless delivery of guide rna molecules and/or guide rna molecule/rna-guided nuclease complex(es) and a production method thereof |
| AU2019327449B2 (en) * | 2018-08-28 | 2026-04-09 | Flagship Pioneering Innovations Vi, Llc | Methods and compositions for modulating a genome |
| KR20210055733A (ko) * | 2018-09-07 | 2021-05-17 | 빔 테라퓨틱스, 인크. | 핵염기 편집 시스템을 전달하기 위한 조성물 및 방법 |
| WO2020191241A1 (en) * | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| WO2021188840A1 (en) | 2020-03-19 | 2021-09-23 | Rewrite Therapeutics, Inc. | Methods and compositions for directed genome editing |
-
2021
- 2021-03-18 WO PCT/US2021/023041 patent/WO2021188840A1/en not_active Ceased
- 2021-03-18 CN CN202180035786.9A patent/CN115667505A/zh active Pending
- 2021-03-18 AU AU2021236683A patent/AU2021236683A1/en active Pending
- 2021-03-18 MX MX2022011562A patent/MX2022011562A/es unknown
- 2021-03-18 JP JP2022555909A patent/JP2023518395A/ja active Pending
- 2021-03-18 EP EP21771405.4A patent/EP4121522A4/en active Pending
- 2021-03-18 KR KR1020227035994A patent/KR20230003467A/ko active Pending
- 2021-03-19 US US17/206,526 patent/US11352623B2/en active Active
- 2021-03-19 US US17/206,522 patent/US11193123B2/en active Active
- 2021-10-20 US US17/506,419 patent/US20220090064A1/en not_active Abandoned
-
2022
- 2022-05-03 US US17/735,929 patent/US20230076357A1/en active Pending
-
2026
- 2026-03-11 JP JP2026038629A patent/JP2026102729A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210292769A1 (en) | 2021-09-23 |
| US20230076357A1 (en) | 2023-03-09 |
| US11352623B2 (en) | 2022-06-07 |
| WO2021188840A1 (en) | 2021-09-23 |
| EP4121522A1 (en) | 2023-01-25 |
| US11193123B2 (en) | 2021-12-07 |
| CN115667505A (zh) | 2023-01-31 |
| AU2021236683A1 (en) | 2022-11-17 |
| EP4121522A4 (en) | 2024-06-19 |
| KR20230003467A (ko) | 2023-01-06 |
| US20220090064A1 (en) | 2022-03-24 |
| JP2026102729A (ja) | 2026-06-23 |
| US20210292753A1 (en) | 2021-09-23 |
| JP2023518395A (ja) | 2023-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3174139A1 (en) | Rna-editing compositions and methods of use | |
| CA3166153A1 (en) | Base editors, compositions, and methods for modifying the mitochondrial genome | |
| MX2025009289A (es) | Inserciones de adn no virales orientadas | |
| MX2021013219A (es) | Celulas que expresan un receptor recombinante de un locus de tgfbr2 modificado, polinucleotidos relacionados y metodos. | |
| PH12021551114A1 (en) | Crispr-cas12j enzyme and system | |
| MX2021004898A (es) | Enzima de crispr/cas12f y sistema novedosos. | |
| WO2020086144A3 (en) | APPLICATIONS OF CRISPRi IN HIGH THROUGHPUT METABOLIC ENGINEERING | |
| EP4431607A3 (en) | High-throughput precision genome editing | |
| BR112022003970A2 (pt) | Métodos e composições para integração genômica | |
| AR123323A1 (es) | Edición genómica de reparación dependiente de homología mejorada | |
| CR20220317A (es) | Anticuerpos anti-cd73 y usos de estos | |
| EP3699280A3 (en) | Novel cas9 systems and methods of use | |
| WO2019089884A3 (en) | Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy | |
| WO2017216771A3 (en) | Crispr-cas system, materials and methods | |
| WO2017193107A3 (en) | Genetically engineered cells and methods of making the same | |
| WO2017070633A3 (en) | Evolved cas9 proteins for gene editing | |
| CL2023000554A1 (es) | Proteínas diseñadas y métodos de uso de las mismas. | |
| WO2022221337A3 (en) | Evolved double-stranded dna deaminase base editors and methods of use | |
| EP4065701A4 (en) | CONSTRUCTS, COMPOSITIONS AND METHODS THEREOF WITH IMPROVED GENOMEDITING EFFICIENCY AND SPECIFICITY | |
| WO2021020884A3 (ko) | 사이토신 염기교정용 조성물 및 이의 용도 | |
| BR112021010781A2 (pt) | Silenciamento genético por meio de edição de genoma | |
| MX2021012966A (es) | Cas9 diseñado con intervalo de dirección de adn ampliado. | |
| CO2024007019A2 (es) | Polinucleótidos, composiciones y métodos para la edición del genoma | |
| MX2024005787A (es) | Edicion genomica por reemplazo directo. | |
| WO2020006131A3 (en) | Nucleases for genome editing |